Envista Holdings Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Envista Holdings Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.57B | Feb 15, 2024 |
| FY2023 | Dec 31, 2022 | $2.57B | Feb 15, 2024 |
| FY2023 | Dec 31, 2021 | $2.51B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.93B | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $2.28B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $2.84B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $2.81B | Feb 21, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.72B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.51B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $2.57B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $2.57B | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | $651.80M | Feb 24, 2022 |
| FY2021 | Oct 1, 2021 | $607.30M | Feb 24, 2022 |
| FY2021 | Jul 2, 2021 | $637.20M | Feb 24, 2022 |
| FY2021 | Apr 2, 2021 | $612.60M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $616.30M | Feb 24, 2022 |
| FY2021 | Oct 2, 2020 | $547.20M | Feb 24, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.37B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.44B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.47B | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | $343.20M | Feb 24, 2022 |
| FY2021 | Oct 1, 2021 | $356.30M | Feb 24, 2022 |
| FY2021 | Jul 2, 2021 | $368.60M | Feb 24, 2022 |
| FY2021 | Apr 2, 2021 | $358.40M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $340.00M | Feb 24, 2022 |
| FY2021 | Oct 2, 2020 | $308.40M | Feb 24, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.12B) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | ($100.20M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $243.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $340.50M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $108.40M | Feb 19, 2021 |
| FY2020 | Oct 2, 2020 | $35.60M | Feb 19, 2021 |
| FY2020 | Jul 3, 2020 | ($93.50M) | Feb 19, 2021 |
| FY2020 | Apr 3, 2020 | ($17.20M) | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | $56.10M | Feb 19, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.10M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.04B) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $31.50M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $319.20M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $306.20M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $43.50M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $235.70M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $298.40M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $386.60M | Feb 21, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.00M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $99.10M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $93.80M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $100.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $100.50M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $86.70M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $133.10M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $172.00M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $172.40M | Feb 21, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.16B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.16B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $1.06B | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $1.06B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.02B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $924.60M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $980.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.13B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.06B | Feb 21, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $275.70M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $336.50M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $275.70M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $182.70M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $361.60M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $283.90M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $397.50M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $400.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $359.10M | Feb 21, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.30M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $33.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $58.20M | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | $75.70M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $54.70M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $47.70M | Feb 16, 2023 |
| FY2021 | Dec 31, 2019 | $77.80M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $72.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $48.90M | Feb 21, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.68B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.35B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $6.61B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.59B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $6.57B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $6.88B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $6.16B | Feb 19, 2021 |
| FY2020 | Dec 31, 2018 | $5.84B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $5.99B | Feb 21, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.11B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.93B | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | $4.17B | Feb 12, 2026 |
| FY2025 | Dec 31, 2022 | $4.21B | Feb 12, 2026 |
| FY2022 | Dec 31, 2021 | $4.06B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.72B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.54B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $4.82B | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.36B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.26B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.29B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.50B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.13B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $3.21B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $3.31B | Feb 19, 2021 |
| FY2020 | Dec 31, 2018 | $3.33B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $3.37B | Feb 21, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($440.40M) | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | ($487.40M) | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $631.20M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $731.40M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $466.90M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $126.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $93.10M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 21, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.07B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $940.00M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $606.90M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.07B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $888.90M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $211.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Feb 21, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.45B | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.39B | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.51B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.38B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.32B | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | $1.79B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.32B | Feb 19, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Oct 1, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Jul 2, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Apr 2, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
| FY2021 | Oct 2, 2020 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | (6) | Feb 12, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 12, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 13, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Oct 1, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Jul 2, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Apr 2, 2021 | 0 | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
| FY2021 | Oct 2, 2020 | 0 | Feb 24, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 163.80M | Feb 12, 2026 |
| FY2025 | Dec 31, 2024 | 172.20M | Feb 12, 2026 |
| FY2024 | Dec 31, 2023 | 171.50M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 163.20M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 161.60M | Feb 16, 2023 |
| FY2021 | Dec 31, 2020 | 160.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 158.70M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 100 | Feb 21, 2020 |